Anti-Inflammatory Naproxen Fails to Prevent Alzheimer’s Progression, Phase 2 Trial Confirms

Anti-Inflammatory Naproxen Fails to Prevent Alzheimer’s Progression, Phase 2 Trial Confirms
Treatment with naproxen, an anti-inflammatory medication, failed to prevent the progression of Alzheimer’s in individuals at risk of developing the disease, results from a Phase 2 clinical trial show. The results, “INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease,” were published recently in Neurology. Alzheimer’s disease is characterized by the accumulation of toxic protein clumps in brain cells, which promote neuroinflammation and ultimately lead to cell death. As such, finding ways to prevent inflammation has been hypothesized as a possible way to delay brain cell death and Alzheimer’s progression. Previous studies have suggested that patients who take nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, have a reduced incidence of Alzheimer’s disease, at least "in relatively young elderly," researchers wrote. Researchers at McGill University's Faculty of Medicine in Canada conducted a Phase 2 trial to explore the safety and effectiveness of low-dose naproxen in pre-symptomatic patients at risk of Alzheimer’s disease. Naproxen is an oral NSAID often used in the clinic, which is sold under several brand names including Naprosyn, Anaprox, and Aleve, among others. The trial, called INTREPAD (NCT02702817), enrolled 195 adult volunteers (mean age 63 years) who had a family history of Alzheimer’s, but still d
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *